Hisamitsu Pharmaceutical Co Inc
Company Profile
Business description
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.
Contact
408 Tashiro Daikan-machi
Tosu
Saga841-0017
JPNT: +81 942832101
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
28 February 2025
Employees
3,682
Stocks News & Analysis
stocks
DeepSeek revelation hits US chip stocks, ASX data centres and uranium
video
What does a weak Aussie dollar mean for investors?
stocks
AI stock rout: The US selloff in 4 charts
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,745.90 | 45.20 | 0.52% |
| CAC 40 | 7,941.64 | 69.16 | 0.88% |
| DAX 40 | 21,727.20 | 89.67 | 0.41% |
| Dow JONES (US) | 44,969.24 | 255.72 | 0.57% |
| FTSE 100 | 8,646.88 | 89.07 | 1.04% |
| HKSE | 20,225.11 | 27.34 | 0.14% |
| NASDAQ | 19,658.22 | 25.90 | 0.13% |
| Nikkei 225 | 39,513.97 | 99.19 | 0.25% |
| NZX 50 Index | 12,928.38 | 74.66 | -0.57% |
| S&P 500 | 6,069.64 | 30.33 | 0.50% |
| S&P/ASX 200 | 8,493.70 | 46.70 | 0.55% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |